Iberia Pharmaceuticals, a leading name in skincare and wellness, has announced the establishment of a state-of-the-art manufacturing and research facility in Jhajjar, Haryana. Spanning 60,000 sq. ft., the next-generation plant is expected to be fully operational by mid-2026.
This ambitious Rs 70-crore investment reinforces the company’s commitment to the Government of India’s ‘Make-in-India’ initiative, reflecting its determination to produce globally competitive, derma-driven wellness solutions within the country.
Equipped for Scale, Committed to Quality
As per the press release, the new facility will feature best-in-class control systems and advanced equipment, ensuring seamless large-scale commercial manufacturing. Backed by a team of experienced professionals, the plant will strictly adhere to international quality standards, even while scaling up operations.
The unit will focus on delivering economically viable, environmentally sustainable, and regulatory-compliant solutions, tailored to the evolving skincare needs of Indian and global consumers.
Science-Led, Consumer-Focused Innovation
At the core of this facility lies a strong focus on research and development. The high-tech labs will continually track market trends, consumer demands, and formulation advancements, supporting the creation of science-backed, personalized skincare products.
These efforts will complement Iberia’s existing discovery capabilities, especially in nanotechnology-driven skincare and therapeutic solutions. With a pharmaceutical-grade foundation, the company remains committed to offering high-performance, vegan skincare products across a wide range of categories.
Strategic Expansion for Global Impact
Nitin Jain, Founder of Iberia Pharmaceuticals, highlighted the strategic importance of this facility, stating,
“By bringing global manufacturing quality to India, we are building trust, capacity, and a future where healthcare meets a higher standard. This plant marks a significant milestone in our journey and aligns with our vision of making world-class products more accessible.”
He added that this facility is one among several strategic initiatives Iberia is implementing to accelerate its global expansion. The company remains firmly rooted in regulatory excellence and operational efficiency.
Boosting Capacity and Employment
Once fully operational, the plant will produce over 12 million units annually in dermatology, wellness, and chronic care segments. In addition, the facility will create over 600 jobs, contributing to regional employment and industrial growth.
Purpose-Driven Skincare with Cutting-Edge Technology
Saurav Ojha, Co-Founder of Iberia Pharmaceuticals, emphasized the company’s unwavering commitment to responsible innovation, saying,
“Our purpose is clear—we aim to deliver healthcare solutions that are precise, safe, and grounded in science. This new facility is a symbol of that commitment and reflects our goal to push the boundaries of innovation using advanced nanotechnology and dermatological research.”
Delivering Trusted Global Brands to Indian Consumers
Iberia also brings a portfolio of clinically tested and globally recognized brands to the Indian market. These include Sesderma, Mediderma, Dermpix, Noreva, and Metacare, among others. These offerings cater to both individual consumers and healthcare professionals, ensuring wide-scale impact across the skincare and wellness ecosystem.
A Legacy of Excellence in Dermatology
With decades of expertise in dermatological care, Iberia Pharmaceuticals has evolved from a single vision into a comprehensive operation. Today, it boasts advanced manufacturing units, R&D facilities, and a robust nationwide distribution network. The company continues to build a reputation as a trusted and innovative leader in dermatology and wellness.
This new facility marks another bold step forward in Iberia’s mission. The company aims to redefine skincare and wellness through science, technology, and trust.